Business
Announcement on the Voluntary Disclosure of Non-Approval of the Marketing Authorization Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis
Announcement on the Voluntary Disclosure of Non-Approval of the Marketing Authorization Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis
About this update from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A
Announcement on the Voluntary Disclosure of Non-Approval of the Marketing Authorization Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary CholangitisThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment